Podcasts

OncLive On Air^® is a podcast from OncLive^® that provides oncology professionals with the resources and information they need to provide the best patient care. Segments cover every angle of oncology practice, from new technology to treatment advances to important regulatory decisions. New episodes with exclusive interviews with leading oncology experts are released on Mondays and Thursdays.

Talking Tumors: Evaluating Early-Stage Breast Cancer Cases in the COVID-19 Era

August 24th 2020

In our exclusive interview, Dr. Meisel and Dr. Hamilton provided insight on key data from the 2020 ASCO Virtual Scientific Program and best practices in managing patients during the coronavirus disease 2019 pandemic.

Talking KRAS-Targeted Therapy in NSCLC With Dr. Levy

August 20th 2020

In our exclusive interview, Dr. Levy discusses the challenges of targeting KRAS and highlighted some of the investigational agents directed toward KRAS G12C mutations that have emerged in the NSCLC pipeline.

Pegram Unpacks Pivotal Data in Breast Cancer

August 17th 2020

In our exclusive interview, Dr. Pegram discusses the unique structure of trastuzumab deruxtecan, initial and subset analyses from the DESTINY-Breast01 trial, potential adverse effects, and recommended management strategies for the agent.

Research Reflections: Braunstein Breaks Down Top ASCO 2020 Abstracts in Myeloma

August 13th 2020

In our exclusive interview, Marc J. Braunstein, MD, PhD, provides perspective on data in the upfront and relapsed/refractory settings regarding the use of triplet and quadruplet regimens, novel agents, and cellular therapies.

Markman and Monk Provide Perspective on the Utility of PARP Inhibitors in Ovarian Cancer

August 10th 2020

In our exclusive interview, Bradley J. Monk, MD, FACS, FACOG, and Maurie Markman, MD, discuss the rationale behind maintenance therapy, pivotal PARP inhibitor trials in the frontline setting, and the importance of shared-decision making.

Dizon Discusses Elements of Sexual Health in Gynecologic Cancer

August 6th 2020

In our exclusive interview, Don S. Dizon, MD, FACP, FASCO, discusses the primary physical and residual psychological effects of gynecologic cancers on women’s sexual health, the challenges of broaching these topics in the clinic, and the role oncologists play in helping patients manage these difficulties.

FDA Approval Insights: Brexucabtagene Autoleucel in Relapsed/Refractory MCL

August 3rd 2020

In our exclusive interview, Michael Wang, MD, discusses the FDA approval of brexucabtagene autoleucel in mantle cell lymphoma and ongoing research aimed at optimizing the safety and persistence of the product.

DiNardo Discusses VIALE-A and Venetoclax Combo in AML

July 30th 2020

In our exclusive interview, Courtney DiNardo, MD, MSCE, discusses the role of venetoclax in acute myeloid leukemia and explains the significance of the results of the VIALE-A trial.

Talking KRAS-Targeted Therapy in NSCLC With Dr. Riess

July 27th 2020

In our exclusive interview, Jonathan W. Riess, MD, MS, discusses the excitement surrounding KRAS G12C inhibitors in non–small cell lung cancer, preliminary efficacy and safety data with AMG 510, and additional research regarding co-mutations and combinations that could lead to further refinement of the potential role of the agent in the landscape.

Examining ADAURA and the Advantages of Adjuvant Osimertinib in EGFR+ NSCLC

July 23rd 2020

In our exclusive interview, Dr. Aggarwal, Dr. Sequist, and Dr. Pennell provided perspective on the results of the ADAURA trial and addressed the potential clinical and financial concerns of using osimertinib in the adjuvant setting in patients with EGFR-mutant NSCLC.

FDA Approval Insights: Selpercatinib in RET+ NSCLC and Thyroid Cancers

July 20th 2020

In our exclusive interview, Alexander Drilon, MD provided background on use of targeted therapy in advanced non–small cell lung cancer, discussed the frequency of RET alterations, and expanded on the data from the LIBRETTO-001 trial that led to the accelerated approval of selpercatinib.

Research Reflections: Sarcoma Experts Consider Emerging Evidence for Novel Combos

July 16th 2020

In our exclusive interview, Shiraj Sen, MD, PhD, and Roman Groisberg, MD, discuss key takeaways from the 2020 ASCO Virtual Scientific Program on exciting efforts being made in the field of sarcoma.

First of its Kind MMRF CureCloud Makes Way for Precision Medicine in Myeloma

July 13th 2020

In our exclusive interview, Dr. Cho and Dr. Ghobrial discuss the inspiration for the MMRF CureCloud, how it advances precision medicine, and the long-term goals of the study for patients and physicians alike.

Marvels in Medicine: Dr. Jordan on Undertaking an Unforeseen Career in Breast Cancer

July 9th 2020

In our exclusive interview, Dr. Jordan explains how he became “The Father of Tamoxifen,” details his work with British Special Forces during the Cold War, and discusses how his career in science started by setting his parents’ house on fire.

FDA Approval Insights: Ramucirumab/Erlotinib in EGFR+ Metastatic NSCLC

July 6th 2020

Edgardo S. Santos, MD, discusses the data that led to the approval of the combination of ramucirumab and erlotinib in EGFR-mutant metastatic non–small cell lung cancer and shared his thoughts on its utility in the frontline setting.

Talking KRAS-Targeted Therapy in NSCLC With Dr. Drilon

July 2nd 2020

In our exclusive interview, Alexander Drilon, MD, discusses some of the historical challenges of targeting KRAS and provided perspective on available and anticipated data with AMG 510 in non–small cell lung cancer.

Research Reflections: Weinberg Weighs in on Thought-Provoking Data in CRC

June 29th 2020

Benjamin Weinberg, MD, shares the clinical implications of how data from the 2020 ASCO Virtual Scientific Program may impact in the treatment of patients with colorectal cancer and projects what the future may hold in the space.

FDA Approval Insights: Olaparib in HRR-Mutant mCRPC

June 25th 2020

In our exclusive interview, Neeraj Agarwal, MD, discusses the recent FDA approval of olaparib in homologous recombination repair–mutant metastatic castration-resistant prostate cancer.

Marvels in Medicine: Vokes’s Venture to Bring Combined Modality Care to Patients With Cancer

June 22nd 2020

In our exclusive interview, Everett Vokes, MD, discusses the path that led him to specialize in head and neck cancer and lung cancer, personal and professional challenges he encountered along the way, and the ultimate importance of bringing multimodality therapy to the forefront of treatment.

Integrating Nutrition Into the Continuum of Cancer Care

June 18th 2020

In our exclusive interview, Dr. Hegazi, shed light on nutrition-related issues among patients with cancer, early intervention strategies for patients who experience loss of muscle mass and function, and the use of specialized nutrients to prevent muscle degradation.